IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?

This review discusses immunomodulatory drug (IMiDs) sequencing and IMiD-free interval strategies for lenalidomide-refractory myeloma. IMiDs and proteasome inhibitors (PIs) improve clinical outcomes in patients with myeloma; however, refractoriness to lenalidomide, a category of IMiD, predicts poor o...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kazuhito, Yano, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672235/
https://www.ncbi.nlm.nih.gov/pubmed/38004369
http://dx.doi.org/10.3390/life13112229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672235/
https://www.ncbi.nlm.nih.gov/pubmed/38004369
http://dx.doi.org/10.3390/life13112229

Ejemplares similares